title: Screening of angiogenesis inhibitors by modified tumor-induced angiogenesis (TIA) test in lung cancer.
abstract: Aberrant angiogenesis-the new vessels formation is a mandatory event in the process of tumor growth and expansion. Studies on mechanisms involved in tumor-induced angiogenesis (TIA) and on its possible inhibitors are needed in order to introduce in future new methods of tumor treatment. The aim of our study was to determine the usefulness of the modified cutaneous TIA (mice without immunosuppression) test for screening in vivo of the angiogenesis modifiers. In both models (classical and modified TIA) we demonstrated comparable angiogenesis activity following human lung cells inoculation and similar degree of neovascularization response inhibition caused by theobromine. We reported that in modified TIA model preincubation with theobromine significantly suppressed angiogenic potential of human lung cancer cells as well as the ability of those cells to produce proangiogenic cytokine-bFGF.
authors.affiliation: Department of Immunology, Surgery, National Institute of Tuberculosis and Lung Diseases, Warsaw.
authors.forename: E
authors.initials: E
authors.lastname: Skopińska-Rózewska
authors.forename: E
authors.initials: E
authors.lastname: Sommer
authors.forename: U
authors.initials: U
authors.lastname: Demkow
authors.forename: J
authors.initials: J
authors.lastname: Chorostowska-Wynimko
authors.forename: B
authors.initials: B
authors.lastname: Bałan
authors.forename: B
authors.initials: B
authors.lastname: Rózycka
authors.forename: E
authors.initials: E
authors.lastname: Barcz
authors.forename: M
authors.initials: M
authors.lastname: Filewska
authors.forename: S
authors.initials: S
authors.lastname: Mlekodaj
authors.forename: P
authors.initials: P
authors.lastname: Rudziński
authors.forename: W
authors.initials: W
authors.lastname: Seweryniak
authors.forename: P
authors.initials: P
authors.lastname: Caban
authors.forename: W
authors.initials: W
authors.lastname: Kupis
authors.forename: J
authors.initials: J
authors.lastname: Bogdan
authors.forename: P
authors.initials: P
authors.lastname: Usiekniewicz
authors.forename: J
authors.initials: J
authors.lastname: Gatarek
authors.forename: R
authors.initials: R
authors.lastname: Langfort
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000368:Aged; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D004354:Drug Screening Assays, Antitumor; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000187:drug effects; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010529:Peritoneal Cavity; D012636:Secretory Rate / Q000187:drug effects; D013805:Theobromine / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009363:Neoplasm Proteins; D016222:Fibroblast Growth Factor 2; D013805:Theobromine